Background: Studies on effectiveness of phytosterol/-stanol-enriched margarines in the community have received low priority. For postlaunch monitoring purposes including risk-benefit analyses, it is needed to investigate both exposure and effectiveness of these margarines. Objective: To study the use and effectiveness of phytosterol/-stanol-enriched margarine. Design, setting and subjects: The study population consisted of 2379 subjects that participated in a community intervention study ('Hartslag Limburg') aged 28-76 years. In 1998 and 2003, blood samples for total and high-density lipoprotein (HDL) cholesterol were obtained. A general questionnaire and food frequency questionnaire (FFQ) were administered. From 1999 onwards, phytosterol/-stanol-enriched margarines were introduced on the Dutch market. On the basis of 2003 data, subjects were classified in users of (a) phytosterol/-stanol-enriched margarine, (b) cholesterol-lowering drugs, (c) the combination (both enriched margarine and drugs) and (d) neither enriched margarines nor cholesterol-lowering drugs. Results: Mean (7s.d.) daily intake of phytosterol-enriched margarine (n ¼ 99) and phytostanol-enriched margarine (n ¼ 16) was 1479 g. From 1998 to 2003, total serum cholesterol concentration changed significantly different among the four groups: in the combination users À2.0471.50 mmol/l (À29%), in cholesterol-lowering drug users À1.0971.17 mmol/l (À17%), in the enriched margarine users À0.2470.75 mmol/l (À4%) and in non-users þ 0.1070.72 mmol/l ( þ 2%)(Po0.05). Conclusion: Recommended doses are not consumed, but phytosterol/-stanol-enriched margarines can modestly reduce serum total cholesterol in the community. These margarines cannot equal the effect of cholesterol-lowering drugs, but may act additively. Further investigation of the health effects that may occur during simultaneous cholesterol lowering drugs and phytosterol-or -stanol-enriched margarines usage is important, as well as community education about the cholesterol lowering foods and drugs.
Introduction
Hypercholesterolemia is a modifiable risk factor for Coronary Heart Disease (CHD) (Neil and Huxley, 2002) . Serum cholesterol levels can be influenced by diet, among others by foods enriched with phytosterols or -stanols through reducing intestinal absorption of cholesterol (Miettinen et al., 1995; Hendriks et al., 1999) , but also by other changes in lifestyle factors such as physical activity and cigarette smoking (2001) . It has been shown that the intake of the recommended amount of 2 g of phytosterols or -stanols per day will reduce low-density lipoprotein (LDL) cholesterol by 9-14% (Law, 2000; Katan et al., 2003) . This effect is primarily established within a few weeks, and has been shown to remain stable for at least 1 year (Katan et al., 2003) . Although no trials have directly tested the effects of phytosterols and -stanols on CHD incidence, data from drug trials indicate that a reduction in LDL-cholesterol level of about 10% could be expected to reduce the population incidence of ischemic heart disease by about 12% to 20% over 5 years (Katan et al., 2003) . Law et al., 1994 even suggested that a reduction in serum total or LDL-cholesterol of 0.6 mmol/l (about 10% for total and 15% for LDL-cholesterol) would reduce mortality from ischemic heart disease by 54% at age 40 to 19% at age 80. More recent publications refer to CHD risk reductions independent of age, varying between 12 and 30% with a 10% to 1.0 mmol/l reduction in LDL level, respectively (Anonymous, 2001; Baigent et al., 2005) .
The effect of phytosterol/ -stanol-enriched margarines appeared to be additive to cholesterol-lowering drugs (Gylling et al., 1997; Blair et al., 2000; Katan et al., 2003) and to be independent of type of diet (Katan et al., 2003) as diet-controlled clinical trials (Neil and Huxley 2002; Perisee 2005) showed the same results as trials in which subjects consumed the margarines as part of their habitual diet (Miettinen et al., 1995; Hendriks et al., 1999; Christiansen et al., 2001; Ntanios et al., 2002 Ntanios et al., , 2003 Vanstone et al., 2002) . Less is known about the effectiveness (efficacy multiplied by compliance) of phytosterol/ -stanol-enriched margarines after market introduction into the communities. Nevertheless, for post-launch monitoring (PLM) purposes (including the monitoring of (un)expected health effects of phytosterol-enriched foods) after marketing and under customary conditions of usage, this type of information is important. (Un)expected (safety) issues on long-term effects, effects in potential risk groups, exposure and prevalence of over-or underconsumption of specific ingredients, and interaction effects with nutrients and/or drugs are major topics for PLM. Hitherto, only one PLM study on phytosterol intake among 2000 households in five West-European countries has been reported in the public domain (Lea and Hepburn, 2006) . This study mainly focused on the type of users and amounts of usage. Unfortunately, results were presented on a household level and not on an individual level and data on effectiveness were lacking. We used an ongoing cohort study in which we were able to identify and characterize the users, and to determine the intake of phytosterol-enriched margarines as well as the effectiveness on the cholesterol levels as parts of PLM. We hypothesized an exposure level and an eventual effectiveness equal to the outcomes found in the randomized clinical 'efficacy' trials.
Methods

Subjects
The study population was a gender-and age-stratified sample of inhabitants of the Maastricht region in the south of the Netherlands, consisting of the city Maastricht and four adjacent municipalities with 13 184 eligible men and women. The eligible subjects participated in earlier monitoring studies focusing on the prevalence of risk factors for chronic diseases in the Dutch population (Verschuren et al., 1994; Houterman et al., 2001) In 1998, 4059 volunteers were invited to participate again in a monitoring study. Although the aim of this study was to evaluate the community intervention Hartslag Limburg, the subjects were informed that the aim of the study was to monitor change in risk factors in adults over a 5-year period. So they were not aware of the underlying aim of the present study. The response rate was 74%, and the final study population consisted of 1480 men and 1520 women aged 23-70 years. Eighty-one percent of these subjects (n ¼ 2414) agreed to participate in a followup study in 2003 (Schuit et al., 2006) . The final study population consisted of 1194 men and 1185 women aged 28-76 years ( Figure 1 ).
Study design
The aim of the community intervention program Hartslag Limburg was to encourage inhabitants to become more active, to reduce their fat intake and to stop smoking. The program had a specific focus on groups with a low socioeconomic status and/or a high risk profile (e.g. diagnosed with cardiovascular diseases or multiple physical risk factors for these diseases). As a consequence of its design, it is not known if and to what extent the subjects in this study were exposed to the community intervention. From 1999 onwards phytostanol and -sterol-enriched margarines were introduced on the Dutch market but this introduction was not a specific part of the intervention program. In 1998 and in 2003, subjects were asked to fill out several questionnaires and were invited for a physical examination at the Maastricht Regional Public Health Service (GGD). Details of the study design are described by Ronda et al. (2004) .
Data collection
The general questionnaire asked for various socio-demographic variables, lifestyle factors (physical activity and smoking behavior), perceived health, history of diseases and cholesterol-lowering drug usage. Familiarity with and opinions on phytosterol/ -stanol-enriched margarines were additional topics in 2003. Physical activity level was measured using an extended version of a validated physical activity questionnaire that was developed for Dutch cohorts within the context of the European Prospective Investigation into Cancer and Nutrition (EPIC) study . Educational level was classified into three categories; low (intermediate secondary education or less), medium (intermediate vocational or higher secondary education) and high (higher vocational or university education). Four questions were included to measure the opinion on the use of functional foods in general, and on the perceived effectiveness and safety of phytosterol/ -stanol-enriched margarines in particular. The five answer categories were recoded into three categories: that is 'totally agree' and 'agree' were regarded as one category, and so were 'disagree' and 'totally disagree'. The 'do not know' answer was treated as the middle category. There were also questions on advantages and disadvantages of functional foods with seven predefined answer categories for both advantages as well as disadvantages, and with one open end category.
The dietary questionnaire was a validated FFQ that was also developed for Dutch cohorts within the context of the European Prospective EPIC study . This semi-quantitative FFQ assessed the habitual consumption of 178 food-items during the previous year. Users of phytosterol/-stanol-enriched margarines were identified by an open question in the FFQ on the brand name of margarine and cooking fat that was commonly consumed in the previous year: that is Becel pro.activ containing phytosterols and Benecol containing phytostanols. The amount of margarine used, was calculated by multiplying the number of slices of bread consumed by the amount of margarine on a slice that was estimated by a series of photographs. The amount of bread spread was added to the amount of cooking fat that was used for dinner preparation. In case on no usage of margarine or cooking fat, or usage of other margarines than the phytostanol-enriched margarine Benecol or the phytosterol-enriched margarine Becel pro.activ, respondents were classified as non-users. No information could be retrieved on the duration of margarine use during the 5 years of follow-up, as phytosterol/ -stanol-enriched margarine use was only recorded in 2003.
The physical examination consisted of anthropometric measurements (weight, height, waist-hip circumference) and measurements of blood pressure. Height was measured to the nearest 0.5 cm without shoes, whereas weight was measured to the nearest 0.5 kg in subjects wearing indoor clothing and no shoes. To adjust for light indoor clothing 1 kg was subtracted from the measured weight. BMI was calculated as weight divided by height squared (kg/m 2 ). Waist circumference was measured with a tape measure in the middle between the bottom of the lower rib and the top of the pelvis. In addition, a non-fasting blood sample was taken in which total cholesterol, and high-density lipoprotein (HDL) cholesterol concentration was determined. Total and HDL cholesterol concentration was determined in serum (Houterman et al., 2001) . Cholesterol determinations were performed in the Lipid Reference Laboratory of the University Hospital in Rotterdam. At baseline, total cholesterol was measured using a CHOD-PAP method (Boehringer) (Kattermann et al., 1984) and HDL cholesterol was determined after precipitation of apoB-containing lipoproteins with phosphotungstic acid/MgCl 2 (Boehringer) (Lopes- Effectiveness of phytosterols/-stanols N de Jong et al Virella et al., 1977) . At follow-up total cholesterol was determined directly and HDL cholesterol was determined using a direct method with lyophilizated reagent. As from 2002 a homogen liquid second generation was used for HDL cholesterol determination (Nauck et al., 1997) . This method has been calibrated against the baseline method ( Blokstra and Verschuren, 2006) . Hypercholesterolemia was defined as a serum total cholesterol concentration of 6.5 mmol/l or higher. For low HDL cholesterol, the cutoff point of 0.9 mmol/l was used (European Atherosclerosis Society, 1987).
Data analyses
As we do not know when users exactly started to use phytosterol/-stanol-enriched margarines, we mainly based our user and non-users descriptions on the 2003 data as this was also the calibration date to determine usage or nonusage. Where appropriate we have presented 1998 data as well. Data on general characteristics and cholesterol concentrations are expressed as mean7s.d. or as absolute numbers and percentages. Differences between phytosterol/ -stanol-enriched margarine users and non-users with respect to socio-demographic, lifestyle and health characteristics as well as with respect to their opinions on these type of foods, were evaluated using Student's independent t-test for continuous variables and using w 2 test for nominal variables.
Analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons was used to compare differences in cholesterol levels and cholesterol changes from 1998 to 2003 between four groups: (a) phytosterol -stanol-enriched margarine users (both Becel pro.activ and Benecol), (b) cholesterol-lowering drug users, (c) combination users (of both phytosterol (Becel pro.activ) and -stanol-(Benecol) enriched margarine and cholesterol-lowering drugs) and (d) non-users (of neither phytosterol/ -stanol-enriched margarine nor cholesterol-lowering drugs). These groups were used to compare the effect of phytosterol/ -stanol-enriched margarine with the effect of cholesterol-lowering drugs. Multiple linear regression analysis was used to investigate the association between phytosterol/ -stanol-enriched margarine usage (g/day, independent variable) and the level of cholesterol lowering per gram of margarine, that is a doseresponse relationship. Covariates were consecutively entered into the model in order of significance in the univariate regression. The following variables were regarded as possible confounders: age, gender, body mass index, waist/hip circumference ratio, saturated, unsaturated and total fat intake, dietary cholesterol intake, energy intake, alcohol intake, smoking behavior, physical activity level, cholesterollowering drugs, diabetes and educational level. The significant covariates were included stepwise in the final model. Besides, an interaction term for phytosterol/ -stanolenriched margarine and cholesterol-lowering drugs was tested in the model, as well as the mean total cholesterol level of baseline and follow-up (to correct regression to the mean). Crude and adjusted models were created for total and HDL cholesterol and for the ratio of total and HDL cholesterol. Data were analyzed using the SAS statistical package version 9.1. A level of significance at Po0.05 (twosided) was used in all analyses.
Results
Phytosterol/ -stanol-enriched margarine use The total study population in 2003 consisted of 2379 subjects. Phytosterol/ -stanol-enriched margarine was used by 115 subjects (5.1%), of which 99 subjects used Becel pro.activ and 16 subjects used Benecol. In total, 50% of the phytosterol/ -stanol-enriched margarine users indeed had a high total cholesterol level before they started to use the enriched margarine compared to 20% of the non-users. Mean habitual daily use for Becel pro.activ as well as for Benecol was 1479 g, ranging from 0.9 to 45 g. Out of the 115 users, 79% ate less than the recommended 20 g per day, whereas 3% exceeded the suggested maximum of 37.5 g enriched margarine per day (equivalent to 3 g of phytosterols/-stanols per day) (Scientific Committee on Food, 2003) . Between men and women there was no statistically significant difference in consumed amounts of enriched margarine (data not shown).
Characteristics of users
Users of enriched margarine were similar to non-users for many characteristics, except for age, dietary fat intake, serum total cholesterol and related variables like measured and selfreported hypercholesterolemia, and experienced CHDs in both in 1998 and 2003 (Table 1) . Users tended to be older (4.5 years, Po0.0001), and had a lower fat intake than nonusers (in 1998: 81 g vs 87 g, Po0.05). Mean serum total cholesterol levels of users were significantly higher than that of non-users both in 1998 (6.47 vs. 5.64 mmol/l, Po0.001) and in 2003 (5.96 vs. 5.62 mmol/l, Po0.001). The majority of respondents were familiar with phytosterol/ -stanol-enriched foods: 100% of the users vs. 77% of the non-users. In total, 96% of the users and 78% of the non-users were of the opinion that it is a good idea to use modern science to develop specific foods with a health promoting effect. Statements and opinions of users vs. non-users are described in Table 2 . It is noteworthy that a substantial part of the users was hesitant about effectiveness and safety of the enriched foods (Table 3) . Especially the non-users were informed by advertisements (51%). Users were also informed by advertisements (35%), but collected additional information through their social network (14%), their GP (12%) or a dietician (10%).
Serum cholesterol concentrations
Phytosterol/-stanol-enriched margarine users, cholesterollowering drug users, combination users and non-users were (Table 4) . Serum baseline total cholesterol concentrations were significantly different for the four groups (ANOVA; Po0.05), with total cholesterol level of combination users (both enriched margarine and cholesterol-lowering Effectiveness of phytosterols/-stanols N de Jong et al drugs) being the highest (7.14 mmol/l) as could be expected. Baseline HDL cholesterol concentrations and the ratio for total and HDL cholesterol were comparable. Among the four groups the changes in total cholesterol from 1998 to 2003 were significantly different (Po0.05), with again the combination users having the largest decrease of 2.04 mmol/l. Cholesterol-lowering drug users had a decrease of 1.09 mmol/l, phytosterol/-stanol-enriched margarine users had a decrease of 0.24 mmol/l, whereas in the nonusers (of neither phytosterol/-stanol-enriched margarine nor cholesterol-lowering drugs) levels increased with 0.10 mmol/ l. The four groups differed also in the proportion of people that reached a decrease in total cholesterol of 10% or more (Po0.05). Seventy-eight percent of the combination users, 63% of cholesterol-lowering drug users, 23% of enriched margarine users, and 14% of non-users achieved this level of decline. No statistically significant difference in the change of total cholesterol concentration from 1998 to 2003 could be detected between moderate users (o20 g of enriched margarine per day and profound users (X20 g of enriched margarine per day)(data not shown). The multiple linear regression analyses showed that phytosterol/-stanolenriched margarine could effectively lower total cholesterol concentration with 0.02 mmol/l per gram of margarine/day, when adjusted for age, gender, cholesterol-lowering drugs, waist/hip circumference ratio and diabetes (Po0.0001) ( Table 5 ). Other covariates did not contribute to the model, including the interaction term for phytosterol/-stanolenriched margarine and cholesterol-lowering drugs.
Discussion
The results of this community study indicate that in free living circumstances phytosterol/ -stanol-enriched margarines can modestly lower serum total cholesterol and the ratio Effectiveness of phytosterols/-stanols N de Jong et al of total and HDL cholesterol. The enriched margarines may even have an additive effect when combined with cholesterollowering drugs. In 1998, 50% of the (future) users of phytosterol/-stanol-enriched margarine had a total serum cholesterol level above 6.5 mmol/l and may represent the manufacturer's target group. The recommended intake for phytosterol/-stanol-enriched margarines is not achieved in free living circumstances. This may be improved by more adequate ways of education about these types of products among consumers belonging to the target group and their intermediates (dieticians, GP's), especially when these products are used in combination with cholesterol-lowering drugs.
In the Maastricht region the prevalence of CHD is higher than for the Dutch country and the socio-economic status of many inhabitants is also slightly lower (Ruland et al., 1999) . As a consequence this region was of high interest to launch a community intervention project focused on improving lifestyle factors (Ronda et al., 2004) . Certainly, the intervention program could have influenced our effectiveness study on phytosterol/ -stanol-enriched margarines in such a way that subjects (both our users and non-users) may have been more aware of their lifestyle, and specifically more aware of their cholesterol levels and risk for cardiovascular diseases. This holds especially for those subjects with a high risk profile. Indeed, the proportion of phytosterol/-stanol-enriched margarine users of 5% was relatively high. For example, in the Doetinchem cohort study (Wolfs et al., 2006) , which served as the control group for this community intervention study only 2% of the subjects used phytosterol/-stanol-enriched margarine in the same study period. According to the Dutch National Food Consumption Survey that was held in 2003 also a usage rate of 2% was found, but these subjects were from a different age category (19-30 years) (Hulshof et al., 2003; de Jong et al., 2005) . In Finland, user-percentages of 3.4% up to 4.7% have been described (Luoto et al., 2004) . Nevertheless, our comparisons with respect to effectiveness between users and non-users within our total study population are still valid. Also, the intake of 14 g of margarine per day in our study was similar to the intake of the control group in Doetinchem, which may imply only a minor cohort study effect (Wolfs et al., 2006) .
Total serum cholesterol levels decreased significantly in phytosterol/ -stanol-enriched margarine users and in combination users (of both phytosterol/ -stanol-enriched margarine and cholesterol-lowering drugs) compared to non-users (of neither phytosterol/ -stanol-enriched margarine nor cholesterol-lowering drugs), which suggests that these types of enriched margarines are effective. This finding is in line with early observations from Patch et al. (2005) , who studied hypercholesterolemic patients in an outpatient clinical practice (Patch et al., 2005) . Their results point out that modifying the diet in these patients in addition to consumption of phytosterol/-stanol-enriched margarines may be more effective on total and HDL cholesterol than dietary modification alone. Unfortunately, this study was underpowered to draw final conclusions.
In our study, serum total cholesterol of phytosterol/-stanol-enriched margarine users decreased with 0.24 mmol/ l (from 6.33 to 6.09 mmol/l, which is approximately 4%). Nevertheless, the estimated margarine effect is higher, as the subjects have turned 5 years older and total cholesterol levels tend to increase with ageing. Indeed in the non-users (of neither phytosterol/ -stanol-enriched margarine nor cholesterol-lowering drugs), total cholesterol increased with 0.10 mmol/l. When this is extrapolated to the phytosterol/ -stanol-enriched margarine users, the estimated enriched margarine effect would be a decrease of 0.34 mmol/l, which is a decrease of 5%. Also, the changes in cholesterol levels only affect LDL-cholesterol levels. So, if the effects would have been expressed in percentage change of LDL-cholesterol levels instead of total cholesterol levels the reduction is almost 6% (70-75% of total cholesterol is LDL-cholesterol). This figure is in line with the established dose-response relationships from clinical trials described earlier, that is an intake of 0.7-1.1 g/day gives an average reduction in LDLcholesterol of 6.7% (95%CI: 4.9-8.6%) (Katan et al., 2003) . Nevertheless, total cholesterol levels of users were still high according to the cholesterol standards despite the use of these enriched margarines. The effect might be smaller, as the mean intake of phytosterol/ -stanol-enriched margarines is lower than recommended (only one in five users ate the recommended 20 g) and may not have been stable during these 5 years, although it is expected that the main decline of LDL-cholesterol occurs within the first weeks. These facts in addition to potential residual confounding may weaken the association. The multiple regression analysis indicated that a decrease of 0.4 mmol/l in total cholesterol level would occur if people consumed 20 g, of margarine per day (0.02 mmol/ l*20 g) which is only slightly lower than expected. One Effectiveness of phytosterols/-stanols N de Jong et al should also keep in mind that there is little additional effect at higher doses than 2.5 g of phytosterols or -stanols per day (E31 g of enriched margarine; (Katan et al., 2003) . Cholesterol-lowering drugs like statins are more effective than phytosterol/ -stanol-enriched margarines (Law, 2000) . This was (not surprisingly) also observed in our study, where a 4.5 times greater decrease of total serum cholesterol was achieved in users of cholesterol-lowering drugs than in users of phytosterol/ -stanol-enriched margarine (À1.09 respectively À0.24 mmol/l). Phytosterol/ -stanol-enriched margarine could be additive to cholesterol-lowering drugs, as was also observed in the cholesterol reduction in the combination users (À2.04 mmol/l). Although the decline in combination users was higher than the sum of the separate effects of phytosterol/ -stanol-enriched margarines and of cholesterollowering drugs, regression analysis revealed no significant interaction between the use of enriched margarine and of cholesterol-lowering drugs. One should realize though that the number of combination users was very small (n ¼ 15). As it is anticipated that the combination users of enriched margarine and cholesterol-lowering drugs had indeed high levels of serum cholesterol at the start of the study (cholesterol-lowering drugs, either in combination with margarines or not, will only be prescribed or advised after at least two independent cholesterol measurements according to the standard GP protocols), the observed significant reductions in serum cholesterol are actual reductions and will not be the result of 'regression to the mean'.
According to the Dutch National Organization for Quality Assurance in Hospitals the ratio of total and HDL cholesterol concentrations is the best indicator to estimate the risk on CHD (Dutch National Organization for Qualitative Assurance in Hospitals (CBO and Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing), 1998), although most clinical trials studied the effect of phytosterol/-stanolenriched margarine on total and LDL-cholesterol. The association between enriched margarine and total/HDL cholesterol ratio was borderline significant in our study. If 20 g of margarine would be consumed daily, a decrease of the ratio of 0.2 would be expected according to our regression model. This would mean that a 3% decrease for phytosterol/ -stanol-enriched margarine users could be achieved, an effect that is still important to be considered in reducing CHD on a population basis.
The proportion of cholesterol-lowering drug users was relatively high in our population, that is 10% in 2003 and 6% in 1998. According to the Dutch national registrations by general practitioners in 2000, 77% of CHD patients used cholesterol-lowering drugs and 660 000 persons in The Netherlands suffered from CHD (National Institute for Public Health and the Environment, 2005) . This would mean that about 3% of the Dutch population used cholesterol-lowering drugs. The discrepancy could be explained by (a) the higher mean age in our population, (b) the results of our intervention program accompanied with the potential increased awareness of high cholesterol levels, and perhaps (c) the general increase of prescriptions of cholesterol-lowering drugs from 2000 to 2003.
As stated earlier, no information was available on the length of margarine use during the 5 years of follow-up, as phytosterol/ -stanol-enriched margarine use was only registered in 2003. Nevertheless, effects will occur only after a couple of weeks of usage and as the FFQ asks for the most frequently used margarine during 1 year we do not think our results are confounded by usage of too short duration. But strictly spoken we are not able to draw conclusions about the 5-years effectiveness of enriched margarines.
For a large part, phytosterol/ -stanol-enriched margarines are consumed by the intended target group. Serum total cholesterol concentrations in the community can be modestly reduced by enriched margarines, without affecting the amount of HDL cholesterol in blood. These types of margarines cannot equal the effect of cholesterol-lowering drugs when consumed in the current amounts, but may act additively to the effect of cholesterol-lowering drugs. The data on exposure and dose-response relationships within the community are valuable information for the current PLM purposes to establish a safety net including risk-benefit analyses. For example, within these PLM activities, the weighing of the pro's and potential cons of simultaneous cholesterol lowering drugs and phytosterol or -stanolenriched margarines usage is important . The net effect of enriched margarines could be optimized when the community is informed more adequately on (intake levels of) phytosterol/ -stanol-enriched margarines. The most adequate ways are yet to be determined.
